<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760121</url>
  </required_header>
  <id_info>
    <org_study_id>H16-00028</org_study_id>
    <nct_id>NCT02760121</nct_id>
  </id_info>
  <brief_title>AZ, MZ, and the Pulmonary System Response to Hypoxia</brief_title>
  <official_title>The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proposal is to compare the physiological effects of acetazolamide (AZ)
      and methazolamide (MZ) on the control of breathing and hypoxic pulmonary vasoconstriction.
      The first objective is to assess the effects of AZ and MZ on the control of breathing in
      normoxia and hypoxia. To achieve this the ventilatory interaction between oxygen and carbon
      dioxide will be measured and effects compared between placebo, AZ, and MZ conditions. In
      addition, the isocapnic and poikilocapnic hypoxic ventilatory response and hypercapnic
      ventilatory response will be measured with each drug. The second objective is to assess the
      effects of AZ and MZ on the control of the pulmonary vasculature during hypoxia. Pulmonary
      pressure and cardiac output will be measured during 60 minutes of poikilocapnic hypoxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ventilation</measure>
    <time_frame>Baseline and 60 minutes of poikilocapnic hypoxia</time_frame>
    <description>To quantify the isocapnic hypoxic ventilatory response, the hypercapnic ventilatory response, and the hypercapnic hypoxic ventilatory response, ventilation will be measured throughout controlled changes in end-tidal gas levels. Each protocol will consist of 90s steps in end-tidal oxygen partial pressure from baseline through 65, 57, and 47 mmHg. For hypercapnic hypoxia, the end-tidal partial pressure for carbon dioxide will be increased from baseline to +6 mmHg for 7 minutes before reducing the end-tidal partial pressure of oxygen as above. The poikilocapnic hypoxic ventilatory response will be determined by measuring the change in ventilation from baseline throughout 60 minutes of poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pulmonary artery pressure</measure>
    <time_frame>Baseline and 60 minutes of poikilocapnic hypoxia</time_frame>
    <description>Pulmonary artery systolic pressure (PASP) will be derived using the modified Bernoulli equation and the regurgitant velocity across the tricuspid valve. Estimates of right atrial pressure will be evaluated based upon the collapsibility index of the inferior vena cave during a sniff test. The pulmonary artery pressure response will be measured during 60 minutes of exposure to poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cerebral blood velocity</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
    <description>To quantify the isocapnic hypoxic cerebral blood velocity response, the hypercapnic cerebral blood velocity response, and the hypercapnic hypoxic cerebral blood velocity response, cerebral blood velocity in the middle and posterior cerebral arteries will be measured throughout controlled changes in end-tidal gas levels. Each protocol will consist of 90s steps in end-tidal oxygen partial pressure from baseline through 65, 57, and 47 mmHg. For hypercapnic hypoxia, the end-tidal carbon dioxide partial pressure will be increased from baseline to +6 mmHg for 7 minutes before reducing the end-tidal oxygen partial pressure as above. The poikilocapnic hypoxic ventilatory response will be determined by measuring the change in ventilation from baseline throughout 60 minutes of poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>change in arterial oxygen partial pressure</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in arterial carbon dioxide partial pressure</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in arterial pH</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in blood pressure</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in end-tidal oxygen and carbon dioxide partial pressure</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in arterial oxygen saturation</measure>
    <time_frame>Baseline and 60 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cardiac output</measure>
    <time_frame>Baseline and 60 minutes of poikilocapnic hypoxia</time_frame>
    <description>Cardiac output will be determined using the aortic time integral velocity and the diameter of the aortic valve annulus. Data will be collected at baseline and throughout exposure to poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in pulmonary venous blood velocity</measure>
    <time_frame>Baseline and 60 minutes of poikilocapnic hypoxia</time_frame>
    <description>Doppler ultrasound will be used to measure the velocity of blood draining from the pulmonary vein at baseline and throughout exposure to poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>albumin</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>iron</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Altitude Sickness</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methazolamide</intervention_name>
    <arm_group_label>Methazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-40 years of age

          -  regularly physically active

          -  male

        Exclusion Criteria:

          -  ex-smokers

          -  pulmonary function &lt;80% of predicted

          -  contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma,
             adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa
             allergy or an electrolyte imbalance such as hyperchloremic acidosis)

          -  Obese (BMI&gt;30Kg/m2)

          -  diuretic medication use

          -  blood thinner use

          -  anti-platelet drug use.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glen E Foster, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1V 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>Methazolamide</keyword>
  <keyword>Control of breathing</keyword>
  <keyword>Hypoxic pulmonary vasoconstriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Methazolamide</mesh_term>
    <mesh_term>Carbonic Anhydrase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

